A5064681916- Inflammatory Bowel Disease
- Microscopic Colitis
- Biosimilars and Bioanalytical Methods
- Liver Diseases and Immunity
- Immunodeficiency and Autoimmune Disorders
- Eosinophilic Esophagitis
- Vascular anomalies and interventions
- Genetic factors in colorectal cancer
- Colorectal Cancer Treatments and Studies
- Pediatric Hepatobiliary Diseases and Treatments
- Diagnosis and treatment of tuberculosis
- Central Venous Catheters and Hemodialysis
- Pregnancy and Medication Impact
- Autoimmune and Inflammatory Disorders Research
- Chronic Lymphocytic Leukemia Research
- Tuberculosis Research and Epidemiology
- Gastrointestinal Bleeding Diagnosis and Treatment
- IL-33, ST2, and ILC Pathways
- Autoimmune and Inflammatory Disorders
Universidade de Passo Fundo
2019-2025
Abstract Background This study aimed to evaluate the real-world, long-term effectiveness and safety of tofacitinib in a large cohort patients with refractory or difficult-to-treat ulcerative colitis (UC). Methods A multicentre, retrospective, observational was conducted, including moderately severely active UC who received for at least 8 weeks. Outcomes assessed included clinical remission response, endoscopic response remission, biochemical steroid-free primary secondary loss drug...
To assess the real-life, long-term effectiveness and safety of tofacitinib in a large cohort patients with refractory or difficult-to-treat ulcerative colitis (UC). This multicenter, retrospective, observational study included moderately to severely active UC who received for at least 8 weeks. Clinical remission response, endoscopic response remission, biochemical steroid-free clinical primary secondary loss drug discontinuation, need dose optimization, colectomy, adverse events were...
Abstract Background The effectiveness of ustekinumab (UST) in the treatment Crohn’s disease (CD) has been demonstrated pivotal Phase 3 UNITI 1 and 2 IM-UNITI studies both anti-TNF-naïve anti-TNF-exposed patients. Given selective nature trial designs, real-world safety are warranted. We report our experience with UST a large, multicenter cohort Brazilian patients CD. Methods performed retrospective study including CD, predominantly biologically refractory who received UST. primary endpoint...
Abstract Background Real-world data on the effectiveness and safety of ustekinumab (UST) in ulcerative colitis (UC) are lacking Latin America. In this study, we aimed to describe UST a real-world multicenter cohort Brazilian patients with UC. Methods We conducted retrospective observational including moderate-to-severe UC (total Mayo score 6–12, an endoscopic subscore 2 or 3) who received UST. The co-primary endpoints were clinical remission, defined as total ≤2 at 1 year, combined rectal...
Abstract Background Real-world data on the effectiveness and safety of ustekinumab (UST) in ulcerative colitis (UC) are lacking Latin America. In this study, we aimed to describe UST a real-world multicentre cohort Brazilian patients with UC. Methods We conducted retrospective observational including moderate severe UC (Total Mayo score 6-12, an endoscopic subscore 2 or 3) who received UST. The co-primary endpoints were clinical remission, defined as total ≤2 at 1 year, combined rectal...
Ustekinumab (UST) is a fully human monoclonal antibody against IL-12/23. UST induced clinical response and maintained higher rate of than placebo in patients with Crohn's disease (CD). was approved Brazil November 2017. Real-world data regarding efficacy safety to CD lacking our country. We report experience use refractory anti-TNF therapy. An open-label prospective not controlled study performed including from five academic medical centres severely active, starting on (IV infusions followed...
Abstract Objective To evaluate the application of proactive pro-drug therapy (TDM) at week six in users infliximab ulcerative colitis patients and to analyze need for further disease optimization. Method This is a retrospective analysis that will be carried out simultaneously Hospital de Clínicas Passo Fundo Endoclin Diagnostic Center city Fundo, with secondary data collection between January 2020 May 2022. The sample included from both sexes, regardless age, who are being followed up...
BACKGROUND: Ustekinumab (UST)is a fully human monoclonal antibody against IL-12/23 approved in Brazil for the treatment of moderate-to-severe Crohn’s disease (CD) November 2017. UST has demonstrated its efficacy induction and maintenance therapy patients with CD. Real world data regarding safety this population is lacking our country. We hereby report experience moderate to severe METHODS: A retrospective chart review prospective study were performed including from eleven IBD referral...
BACKGROUND: Real world data regarding long-term effectiveness and safety of ustekinumab (UST) for the treatment Crohn’s disease (CD) is lacking in South America. We report outcomes a Brazilian multicentre retrospective cohort patients with moderate-to-severe CD treated UST real-world setting. METHODS: Between November 2017 December 2019, study was performed including from 12 inflammatory bowel (IBD) academic medical centers diagnosed moderately to severely active starting on (weight-based...